The present invention relates novel binding molecules comprising a ubiquitin mutein (Affilin? and a monoclonal antibody or antibody fragment. The invention refers to bispecific and/or bivalent binding proteins or to a therapeutically or diagnostically active component. The invention further relates to the use of these binding proteins' medicine, preferably for use in the treatment of cancer or autoimmune disorders.